Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.
Tenofovir (TFV), a nucleotide reverse transcriptase inhibitor, requires two phosphorylation steps to form a competitive inhibitor of HIV reverse transcriptase. Adenylate kinase 2 (AK2) has been previously demonstrated to phosphorylate tenofovir to tenofovir-monophosphate, while creatine kinase, musc...
Main Authors: | Dominique B Figueroa, Joseph Tillotson, Maoji Li, Estelle Piwowar-Manning, Craig W Hendrix, Timothy H Holtz, Kevin Bokoch, Linda-Gail Bekker, Frits van Griensven, Sharon Mannheimer, James P Hughes, Robert M Grant, Namandjé N Bumpus |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5895070?pdf=render |
Similar Items
-
Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner
by: Julie M. Lade, et al.
Published: (2015-09-01) -
A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention
by: Priya Jayachandran, et al.
Published: (2021-03-01) -
A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
by: Kuo-Hsiung Yang, et al.
Published: (2014-01-01) -
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand.
by: Michael Martin, et al.
Published: (2011-01-01) -
Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052.
by: Philip J Palumbo, et al.
Published: (2017-01-01)